Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
MeSH Number(s)
D27.505.519.186.071.202.370
D27.505.519.389.370
D27.505.954.557.500.202.370
Concept/Terms
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Reductase Inhibitors, HMG-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Harvard Catalyst Profiles by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 1 | 3 | 4 |
| 1995 | 0 | 1 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 7 | 1 | 8 |
| 1999 | 3 | 1 | 4 |
| 2000 | 13 | 6 | 19 |
| 2001 | 16 | 4 | 20 |
| 2002 | 30 | 4 | 34 |
| 2003 | 29 | 12 | 41 |
| 2004 | 32 | 9 | 41 |
| 2005 | 46 | 4 | 50 |
| 2006 | 45 | 24 | 69 |
| 2007 | 52 | 16 | 68 |
| 2008 | 40 | 25 | 65 |
| 2009 | 51 | 13 | 64 |
| 2010 | 55 | 19 | 74 |
| 2011 | 69 | 26 | 95 |
| 2012 | 68 | 22 | 90 |
| 2013 | 68 | 23 | 91 |
| 2014 | 85 | 22 | 107 |
| 2015 | 104 | 28 | 132 |
| 2016 | 58 | 35 | 93 |
| 2017 | 90 | 27 | 117 |
| 2018 | 84 | 26 | 110 |
| 2019 | 69 | 35 | 104 |
| 2020 | 65 | 35 | 100 |
| 2021 | 56 | 11 | 67 |
| 2022 | 16 | 1 | 17 |
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Strengthening a Study of Diabetes Progression After Statin Use. JAMA Intern Med. 2022 Apr 01; 182(4):459-460.
-
Associations of statin use with 30-day adverse outcomes among 4?801?406 US Veterans with and without SARS-CoV-2: an observational cohort study. BMJ Open. 2022 03 18; 12(3):e058363.
-
SGLT2 inhibitors: the statins of the 21st century. Eur Heart J. 2022 03 14; 43(11):1029-1030.
-
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. J Am Heart Assoc. 2022 03 15; 11(6):e022937.
-
Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries. Diabetes Care. 2022 03 01; 45(3):604-613.
-
Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022 03; 10(3):e369-e379.
-
Frailty and cardiovascular mortality in more than 3 million US Veterans. Eur Heart J. 2022 02 22; 43(8):818-826.
-
Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. J Am Coll Cardiol. 2022 02 22; 79(7):617-628.
-
Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovasc Res. 2022 02 21; 118(3):897-903.
-
Statin Use in Pregnancy: Is It Time For a Paradigm Shift? Circulation. 2022 02 15; 145(7):496-498.